Microbot Medical Target of Unusually High Options Trading (NASDAQ:MBOT)

Microbot Medical Inc. (NASDAQ:MBOT - Get Free Report) was the recipient of unusually large options trading on Tuesday. Investors purchased 4,407 call options on the stock. This is an increase of approximately 246% compared to the typical volume of 1,272 call options.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Wall Street Zen raised Microbot Medical from a "sell" rating to a "hold" rating in a research report on Saturday, June 14th. HC Wainwright reaffirmed a "buy" rating and set a $9.00 price objective on shares of Microbot Medical in a research report on Thursday, April 10th.

Hedge Funds Weigh In On Microbot Medical

Institutional investors and hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC purchased a new position in Microbot Medical during the first quarter valued at $42,000. Goldman Sachs Group Inc. purchased a new position in shares of Microbot Medical in the first quarter valued at about $57,000. Renaissance Technologies LLC purchased a new position in shares of Microbot Medical in the fourth quarter valued at about $118,000. Finally, Geode Capital Management LLC lifted its position in shares of Microbot Medical by 7.9% in the fourth quarter. Geode Capital Management LLC now owns 142,659 shares of the biotechnology company's stock valued at $160,000 after acquiring an additional 10,442 shares in the last quarter. 16.30% of the stock is currently owned by hedge funds and other institutional investors.

Microbot Medical Price Performance

MBOT stock traded down $0.02 on Friday, reaching $2.62. 1,240,840 shares of the company traded hands, compared to its average volume of 1,790,906. Microbot Medical has a one year low of $0.82 and a one year high of $3.38. The company has a market cap of $95.32 million, a P/E ratio of -4.03 and a beta of 1.13. The firm has a fifty day simple moving average of $2.56 and a 200-day simple moving average of $2.07.

Microbot Medical (NASDAQ:MBOT - Get Free Report) last posted its earnings results on Wednesday, May 21st. The biotechnology company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.07. On average, sell-side analysts forecast that Microbot Medical will post -0.71 EPS for the current year.

About Microbot Medical

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.